Tag: Human Papillomavirus (HPV)
Sex, Race, Age Disparities in Survival for HPV-Linked Cancer
Whites have consistently higher five-year survival than blacks for all cancers across all age groups
Risk of ≥CIN3 Drops With Negative HPV, Cytology Co-Tests
Decrease in 5-year ≥CIN3 risks after each successive negative round of HPV, cytology co-testing
HPV Vaccine Tied to Reduced Respiratory Papillomatosis Rate
Reduction in incidence of juvenile-onset recurrent respiratory papillomatosis from 2012 to 2016
Oncogenic Oral HPV DNA Detected in 3.5 Percent of Adults
Prevalence of oncogenic oral HPV higher in men, rises with number of lifetime oral sexual partners
Prevalence of Oral HPV Infection Higher for U.S. Men
Overall prevalence 11.5 percent in men, 3.2 percent in women; high-risk HPV also more prevalent in men
HPV Vaccination After Lesion Treatment Is Likely Cost-Effective
Adjuvant HPV vaccination could reduce anal cancer risk in HIV-infected men who have sex with men
ASTRO: Aggressive Reduction of Radiation Beneficial in OPSCC
In HPV-related disease, the approach linked to high cure rates, reduced side effects
USPSTF Backs Cervical Cancer Screening With Cytology or hrHPV
Recommendations for screening with cytology alone every three years or hrHPV testing every five years
Vaccine-Type HPV Rates Down for Unvaccinated Young Women
Significant decrease among unvaccinated women aged 18 to 26 years from 2009-2010 to 2013-2014
CDC: More U.S. Teens Starting HPV Vaccination
60.4 percent received one or more doses in 2016, but many not completing series
